Faculty

Institution

Unit

Venue

Xiaohong Leng

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

NoneXiaohong Leng is currently serving as a Hematopoietic Biology And Malignancy faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Xiaohong Leng

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

cancer research cell biology immunology cancer biology tumor biology oncogenes leukemia pharmacology oncology hematological malignancies medicinal research molecular biology hematology cancer cells cancer immunotherapy therapeutic targets cell signaling metastasis cellular therapy enzyme inhibition myeloid neoplasia stem cell research molecular cell biology tumor suppressors receptor tyrosine kinases tumor targeting molecular cancer cancer care therapeutic efficacy cancer genetics breast oncology cancer treatment cell regulation anti-cancer agents peptides clinical chemistry cell death medical mycology gynecologic oncology biological chemistry therapy resistance signaling pathways mesenchymal stem cells cancer genomics gene regulation inhibitory activity oncogenic agent malignant disease novel therapies cancer immunosurveillance clinical immunology antibody engineering clinical mycology hla typing myelopoiesis malignant blood disorders treatment and prevention chronic inflammation adult t-cell leukemia-lymphoma breast cancer growth tissue-resident stem cells bcr-abl-induced tumorigenesis lipocalin 2 bcr-abl1 mediates up-regulation dual functions tyrosine kinase inhibitors androgen receptor ngal expression leukemia cells network complex hsp90 inhibitors effective therapeutic option lyn kinase phase ii study mrd-positive aml

Notable Scholarly Works

Notable Federal Grants

Collaborators

1228 Immune Escape Through Oncogene-Mediated Editing of the Hla-Ligandome. Regular and Young Investigator Award Abstracts (2025)

immunologyhla typingimmune responsesimmune escapecell transplantation

Asxl1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack. bioRxiv (Cold Spring Harbor Laboratory) (2025)

immunologycarcinogenesishematological malignanciesleukemiatumor biologyadult t-cell leukemia-lymphomat cell attackmolecular cell biologymolecular biologyimmune responsesoncogenesmutagenesis (molecular biology technique)molecular medicinecell biology

A Phase II Study of Vibecotamab, a Cd3-Cd123 Bispecific T-Cell Engaging Antibody, for Mrd-Positive Aml and Mds After Hypomethylating Agent Failure.. Journal of Clinical Oncology (2023)

Nicholas James ShortPavan BachireddyXuelin HuangHyunsoo HwangXiaohong LengJaehyun LeeDanielle NguyenGuillermo Garcia-ManeroCourtney Denton DinardoGautam BorthakurTapan M. KadiaNaval Guastad DaverGhayas C. IssaAbhishek MaitiFarhad Ravandi

gynecologic oncologyphase ii studyantibody engineeringtumor targetingmedicinecancer carecancer immunosurveillanceclinical mycologycancer researchcancer immunotherapyimmunotherapyimmunologymedical mycologymrd-positive amlpharmacologyclinical immunologyoncologyclinical researchmedicinal researchcellular therapy

Data From Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. (2023)

Xiaohong LengTian DingHui LinYan WangLimei HuJianhua HuBarry FeigWei ZhangLajos PusztaiW. Fraser SymmansYun WuRalph B. Arlinghaus

treatment and preventionneurologydermatologyenzyme inhibitionpharmacologymetastasistumor targetingcancer researchvascular biologyreceptor tyrosine kinasestherapeutic targetscellular therapyanti-cancer agentsbreast cancermedicinal researchcancer cellscancer biologytumor biology

Data From Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. (2023)

Sobeyda B. Gomez-ChouAgnieszka Katarzyna Swidnicka-SiergiejkoNiharika BadiMyrriah Chavez-TomarGregory B. LesinskiTanios Bekaii-SaabMatthew R. FarrenThomas A. MaceCarl SchmidtYan LiuDefeng DengRosa F. HwangLiran ZhouTodd MooreDeyali ChatterjeeHuamin WangXiaohong LengRalph B. ArlinghausCraig D. LogsdonZobeida Cruz-Monserrate

dermatologypharmacologycell regulationcancer researchlipidschronic inflammationdata sciencetumor microenvironmentmedicinal researchcancer biologytumor biologyinflammation

Supplementary Figure 3 From Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. (2023)

Xiaohong LengTian DingHui LinYan WangLimei HuJianhua HuBarry FeigWei ZhangLajos PusztaiW. Fraser SymmansYun WuRalph B. Arlinghaus

tumor targetingreceptorsenzyme inhibitionmetastasispharmacologyradiation oncologycancer researchanti-cancer agentsbreast cancercancer biologytumor biology

Abstract 122: Targeting Forward and Reverse Ephb4/Efnb2 Signaling by a Peptide With Dual Functions. Cancer Research (2020)

Chiyi XiongYunfei WenJun ZhaoDengke YinLingyun XuAnca Chelariu-RaicuCody YaoXiaohong LengJinsong LiuRajan R ChaudhariShuxing ZhangAnil K SoodChun Li

signaling pathwayspeptidesdual functionscancer biologycancer researchmolecular biologysignal transduction

Roles of P53, Nf-κB and the Androgen Receptor in Controlling Ngal Expression in Prostate Cancer Cell Lines. Advances in Biological Regulation (2018)

William H. ChappellSaverio CandidoStephen L. AbramsSuzanne RussoRoger OveAlberto M. MartelliLucio CoccoGiulia RamazzottiMelchiorre CervelloGiuseppe MontaltoLinda S. SteelmanXiaohong LengRalph B. ArlinghausMassimo LibraJames A. McCubrey

neurologygene expressionpharmacologycancer geneticscell regulationtumor biologycancer genomicsandrogen receptoroncologyneuro-oncologyoncogenescancer cellsngal expressioncancer biologyprostate cancergene regulationcell biology

Combination of Jak2 and Hsp90 Inhibitors: An Effective Therapeutic Option in Drug-Resistant Chronic Myelogenous Leukemia. Genes & Cancer (2016)

hematological malignanciesleukemiapharmacologymyeloid neoplasiahematologycancer researchnovel therapiestherapeutic targetseffective therapeutic optiononcogeneshsp90 inhibitorscell biology

Hsp90 Inhibitor Auy922 Induces Cell Death by Disruption of the Bcr-Abl, Jak2 and Hsp90 Signaling Network Complex in Leukemia Cells. Genes & Cancer (2015)

Wenjing TaoSandip N. ChakrabortyXiaohong LengHelen MaRalph B. Arlinghaus

autoimmune diseasesinhibitory activityoncogenic agentnetwork complexcell biologyleukemia cellsstem cell researchcancer biologyleukemiacancer researchtumor suppressorstherapeutic targetscancer immunotherapyimmunologyenzyme inhibitionmalignant diseasemolecular biologyoncologyoncogenesmedicinal research

1
2
3
10 / page

Xiaohong Leng

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

NoneXiaohong Leng is currently serving as a Hematopoietic Biology And Malignancy faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Xiaohong Leng

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

1228 Immune Escape Through Oncogene-Mediated Editing of the Hla-Ligandome. Regular and Young Investigator Award Abstracts (2025)

immunologyhla typingimmune responsesimmune escapecell transplantation

Asxl1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack. bioRxiv (Cold Spring Harbor Laboratory) (2025)

A Phase II Study of Vibecotamab, a Cd3-Cd123 Bispecific T-Cell Engaging Antibody, for Mrd-Positive Aml and Mds After Hypomethylating Agent Failure.. Journal of Clinical Oncology (2023)

Data From Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. (2023)

Xiaohong LengTian DingHui LinYan WangLimei HuJianhua HuBarry FeigWei ZhangLajos PusztaiW. Fraser SymmansYun WuRalph B. Arlinghaus

Data From Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. (2023)

dermatologypharmacologycell regulationcancer researchlipidschronic inflammationdata sciencetumor microenvironmentmedicinal researchcancer biologytumor biologyinflammation

Supplementary Figure 3 From Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. (2023)

Xiaohong LengTian DingHui LinYan WangLimei HuJianhua HuBarry FeigWei ZhangLajos PusztaiW. Fraser SymmansYun WuRalph B. Arlinghaus

tumor targetingreceptorsenzyme inhibitionmetastasispharmacologyradiation oncologycancer researchanti-cancer agentsbreast cancercancer biologytumor biology

Abstract 122: Targeting Forward and Reverse Ephb4/Efnb2 Signaling by a Peptide With Dual Functions. Cancer Research (2020)

Chiyi XiongYunfei WenJun ZhaoDengke YinLingyun XuAnca Chelariu-RaicuCody YaoXiaohong LengJinsong LiuRajan R ChaudhariShuxing ZhangAnil K SoodChun Li

signaling pathwayspeptidesdual functionscancer biologycancer researchmolecular biologysignal transduction

Roles of P53, Nf-κB and the Androgen Receptor in Controlling Ngal Expression in Prostate Cancer Cell Lines. Advances in Biological Regulation (2018)

Combination of Jak2 and Hsp90 Inhibitors: An Effective Therapeutic Option in Drug-Resistant Chronic Myelogenous Leukemia. Genes & Cancer (2016)

hematological malignanciesleukemiapharmacologymyeloid neoplasiahematologycancer researchnovel therapiestherapeutic targetseffective therapeutic optiononcogeneshsp90 inhibitorscell biology

Hsp90 Inhibitor Auy922 Induces Cell Death by Disruption of the Bcr-Abl, Jak2 and Hsp90 Signaling Network Complex in Leukemia Cells. Genes & Cancer (2015)

Wenjing TaoSandip N. ChakrabortyXiaohong LengHelen MaRalph B. Arlinghaus

1
2
3
10 / page